Why the study?
The effects of cardiac contractility modulation therapy on myocardial mechano-energetic efficiency and global longitudinal strain in patients with HFrEF are unknown.
Does cardiac contractility modulation therapy improve left ventricular global longitudinal strain and myocardial mechano-energetic efficiency in patients with HFrEF?
Does cardiac contractility modulation therapy improve left ventricular global longitudinal strain and myocardial mechano-energetic efficiency in patients with HFrEF?
Cardiac contractility modulation therapy improves left ventricular performance, including ejection fraction, global longitudinal strain, and mechano-energetic efficiency in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
CCM may enhance efficiency in HFrEF; hypothesis-generating and requires larger randomized confirmation before practice change.
Background: Virtually all patients with heart failure with reduced ejection fraction have a reduction of myocardial mechano-energetic efficiency (MEE). Cardiac contractility modulation (CCM) is a novel therapy for the treatment of patients with HFrEF, in whom it improves the quality of life and functional capacity, reduces hospitalizations, and induces biventricular reverse remodeling. However, the effects of CCM on MEE and global longitudinal strain (GLS) are still unknown; therefore, this study aims to evaluate whether CCM therapy can improve the MEE of patients with HFrEF. Methods: We enrolled 25 patients with HFrEF who received an Optimizer Smart implant (the device that develops CCM therapy) between January 2018 and January 2021. Clinical and echocardiographic evaluations were performed in all patients 24 h before and six months after CCM therapy. Results: At six months, follow-up patients who underwent CCM therapy showed an increase of left ventricular ejection fraction (30.8 ± 7.1 vs. 36.1 ± 6.9%; p = 0.032) as well a rise of GLS 10.3 ± 2.7 vs. −12.9 ± 4.2; p = 0.018), of MEE (32.2 ± 10.1 vs. 38.6 ± 7.6 mL/s; p = 0.013) and of MEE index (18.4 ± 6.3 vs. 24.3 ± 6.7 mL/s/g; p = 0.022). Conclusions: CCM therapy increased left ventricular performance, improving left ventricular ejection fraction, GLS, as well as MEE and MEEi.
No takes yet. Share an insight, caveat, or question.
Masarone et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: